Catalog No.
Product Name
Application
Product Information
Citations
-
Antibacterial Agent
Antibacterial Agent 104 is a potent antibacterial compound primarily targeting bacterial pathogens. Demonstrating excellent in vitro antibacterial activity, it also exhibits significant efficacy in vivo against methicillin-resistant Staphylococcus aureus (MRSA). This compound is valuable for research focused on developing treatments for bacterial infections and studying antibiotic resistance mechanisms. -
Bacterial Inhibitor
MT0703 is an aminothiazolyl glycyl cephalosporin that targets bacterial pathogens, exhibiting potent anti-Pseudomonas activity. This compound is studied for its potential in understanding bacterial resistance mechanisms and developing novel therapeutic strategies. Its structure, featuring a 1,5-dihydroxy-4-pyridone-2-carbonyl group, enhances its efficacy against a range of bacterial infections. -
Polyene-Like Antibiotic
Monazomycin is a polyene-like antibiotic produced by the actinobacterium Streptomyces. It exhibits potent antimicrobial activity against a range of pathogenic fungi and can be utilized in research applications focused on antifungal mechanisms. Its unique molecular structure and weight of approximately 1200 Daltons facilitate studies in antibiotic action and resistance. Monazomycin is valuable for elucidating cell membrane interactions and understanding the therapeutic potential of polyene antibiotics. -
Antibiotic
Cefpodoxime sodium is a broad-spectrum antibiotic that targets bacterial cell wall synthesis, effectively inhibiting the growth of both gram-positive and gram-negative bacteria. This compound demonstrates significant antibacterial activity, making it suitable for research applications in conditions such as acute otitis media, sinusitis, and tonsillopharyngitis. Cefpodoxime sodium serves as an important tool in microbiological studies and antibiotic resistance research. -
Antibiotic
Ranbezolid hydrochloride is an oxazolidinone antibiotic that targets the bacterial 50S ribosomal subunit, exhibiting an IC50 of 17 μM against bacterial ribosomes. This compound effectively combats Gram-positive and Gram-negative anaerobes, including strains such as Staphylococcus aureus, Staphylococcus epidermidis, and Bacteroides fragilis. Ranbezolid disrupts cell wall and lipid synthesis, demonstrating rapid bactericidal effects and significant reductions in bacterial load. It is particularly valuable for research involving antibiotics against anaerobic bacterial infections. -
Antibiotic
Cephalochromin is an antibiotic that acts as a specific inhibitor of bacterial fatty acid synthase (FabI). It demonstrates potent inhibitory activity against Staphylococcus aureus and Escherichia coli, with IC50 values of 1.9 µM and 1.8 µM, respectively. Additionally, Cephalochromin is effective against gram-positive methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant S. aureus (QRSA), exhibiting minimum inhibitory concentrations (MIC) in the range of 2-8 µg/mL. This compound is useful in research focused on antibiotic resistance and fatty acid biosynthesis in bacteria. -
Fluoroquinolone Antibiotic
Tosufloxacin tosylate is a fluoroquinolone antibiotic that targets bacterial DNA gyrase and topoisomerase IV, inhibiting bacterial DNA synthesis. This compound exhibits a broad spectrum of antibacterial activity against both gram-positive and gram-negative microorganisms. It is suitable for research applications involving the study of bacterial infections and the mechanisms of antibiotic resistance. -
Antibiotic
Cefuracetime is a cephalosporin antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins. It demonstrates significant antibacterial activity against a range of Gram-positive and Gram-negative pathogens. Cefuracetime is utilized primarily in research applications focused on understanding antibiotic resistance mechanisms and evaluating the efficacy of antibiotic compounds. -
Antibiotic
Josamycin propionate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It exhibits potent antibacterial activity against a range of Gram-positive and some Gram-negative bacteria. This compound is utilized in microbiological studies and clinical research focusing on antibiotic resistance and the efficacy of novel therapeutic agents. -
Antibiotic
TMA-230 is a penem antibiotic with oral bioavailability, primarily targeting bacterial infections. It exhibits potent antibacterial activity, making it valuable for research focused on combating infection. TMA-230 is suitable for studies exploring the mechanisms of antibiotic resistance and the development of new therapeutic strategies against resistant pathogens. -
Antibacterial
GT-1 is a siderophore-linked cephalosporin with notable antibacterial activity. It demonstrates efficacy against clinically significant isolates, including Pseudomonas aeruginosa, Klebsiella oxytoca, Proteus species, Serratia marcescens, and Enterobacter aerogenes. This compound is valuable for research applications focusing on antibiotic resistance and the development of novel antibacterial therapies. -
Antibiotic
Efrotomycin is an orally active antibiotic derived from Streptomyces lactamdurans. It exhibits selective antibacterial activity, although studies indicate it has an insignificant effect on Salmonella typhimurium in terms of quantity, duration, shedding rate, and antimicrobial susceptibility in infected swine. This compound is primarily utilized in research focused on antibiotic efficacy and microbial resistance mechanisms. -
Antibiotic
Kijimicin is a polyether antibiotic that exerts its antibacterial effects by inhibiting protein synthesis in susceptible microorganisms. It is particularly effective against a range of Gram-positive bacteria and some Gram-negative strains, contributing to its utility in antimicrobial research. Kijimicin's ability to combat bacterial infections makes it valuable for studies focused on antibiotic resistance and the development of new therapeutic strategies. -
Antitumor Antibiotic
LL-C 10037α is an antitumor antibiotic derived from the bacterium Streptomyces. This compound has demonstrated significant cytotoxic activity against various cancer cell lines, making it a valuable tool in cancer research. Its unique mechanism of action can assist in exploring therapeutic strategies for tumor treatment and understanding the underlying cellular processes in oncology. -
Antibiotic
Ruboxyl is an anthracycline antibiotic that exhibits significant antitumor activity. It effectively inhibits colorectal cancer liver metastasis by 84% in murine models, suppresses B16 melanoma growth, and enhances survival rates in mice with L1210 and L5178Y leukemia. This compound is useful for exploring mechanisms of tumor biology and developing potential therapeutic strategies for various cancers. -
Antibiotic
Mycinamicin I is a macrolide antibiotic that exerts its antimicrobial activity by inhibiting bacterial protein synthesis. It targets the 50S ribosomal subunit, effectively disrupting the translation process in susceptible bacteria. Mycinamicin I is utilized in research applications focused on antibiotic resistance, bacterial genetics, and the development of novel antimicrobial therapies. -
Antibiotic
Leucomycin A1 is an antibiotic derived from the leucomycin complex produced by Streptomyces kitasatoensis. It exhibits potent antibacterial activity against various Gram-positive bacteria, making it a valuable reagent for microbiological research. Its mechanism of action involves inhibition of protein synthesis, thus providing insights for studies related to antimicrobial resistance and the development of new therapeutic agents. -
Carbapenem Antibiotic
DU-6681 is a carbapenem antibiotic characterized by its broad-spectrum and potent in vitro antibacterial activity against a wide range of gram-positive and gram-negative bacteria. This compound serves as the active parent of DZ-2640 and is valuable for antibacterial research, particularly in studies investigating resistance patterns and efficacy against pathogenic strains. Its robust pharmacological profile makes it an important tool for further exploration in antibiotic development and microbiology. -
Antibiotic
Cefuzonam sodium is a second-generation cephalosporin antibiotic that exhibits antimicrobial activity against Staphylococcus aureus, particularly strains resistant to third-generation cephalosporins. Its primary application includes the prevention of postoperative infections, notably following cesarean deliveries. This compound is valuable in clinical settings for managing bacterial infections where resistance is a concern. -
Antibiotic
Actiphenol is an antibiotic that primarily targets coxsackievirus B3 and influenza A virus, demonstrating IC50 values of 14.37 µg/mL and 34.4 µg/mL, respectively. This compound is an aromatic ketone with weak inhibition activity on eukaryotic translation, sourced from Streptomyces species. Actiphenol serves as a key intermediate in the synthesis of Cycloheximide, making it a valuable reagent in various research applications, including studies on viral infections and translation dynamics. -
Antibiotic
Saccharocarcin B is a macrocyclic lactone antibiotic that primarily targets Gram-positive bacteria, demonstrating significant activity against Micrococcus luteus and Staphylococcus aureus, as well as against the Gram-negative bacterium Chlamydia trachomatis. Its unique structural properties enable it to disrupt essential bacterial processes, making it a valuable reagent for antimicrobial research. Saccharocarcin B is useful in studies focusing on antibiotic resistance and the development of new therapeutic strategies against bacterial infections. -
Antibiotic
6"-Deamino-6"-hydroxyneomycin B is an aminoglycosyl antibiotic targeting bacterial protein synthesis. It exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable compound for microbiological studies. Additionally, it serves as an important intermediate in the biosynthesis of neomycin, facilitating research into antibiotic production and modification. -
Antibiotic
Kidamycin is a polymyxin antibiotic known for its antimicrobial properties. It exhibits effective antibacterial activity against a range of Gram-negative bacteria, making it valuable in research applications focused on antibiotic resistance and infectious disease. Its unique chemical structure allows for the exploration of mechanisms of action in microbiological studies. -
Antibiotic
Nafcillin sodium is a β-lactam antibiotic effective in inhibiting β-lactamase enzymes. This agent demonstrates significant antibacterial activity against penicillinase-producing staphylococci, making it valuable for studying staphylococcal infections and antibiotic resistance mechanisms in microbial research. Its applications extend to investigating therapeutic options in treating resistant bacterial infections. -
Antibiotic
Ferrocin B is an iron-containing cyclic decapeptide antibiotic that targets Gram-negative bacteria, exhibiting potent antibacterial activity, especially against Pseudomonas aeruginosa. It demonstrates a half effective dose (ED50) of 0.593 mg/kg in a murine infection model against P. aeruginosa. Ferrocin B is an important tool for research in anti-infective therapies and may contribute to the development of novel antimicrobial strategies. -
Antibiotic
Berkeleylactone F is an antibiotic macrolide that exhibits activity against certain cancer cell lines. Notably, it demonstrates modest inhibitory effects on CCRF-CEM leukemia cells, making it a valuable compound for research in cancer pharmacology and antibiotic mechanisms. Its unique structure can facilitate studies on antibiotic resistance and cellular response to macrolide treatment. -
Antibiotic/Antimicrobial Peptide
Aurein 3.2 is an antimicrobial peptide that exhibits potent antibiotic activity against a range of bacterial pathogens. In addition to its bactericidal properties, Aurein 3.2 demonstrates anticancer activity, making it a valuable compound for research in both infectious disease and cancer therapeutics. Its unique mechanism of action and dual functionality make it an important tool for exploring therapeutic applications in microbiology and oncology. -
Antitumor Antibiotic
Luzopeptin A is an actinoleukin-like antitumor antibiotic that functions primarily as a bifunctional DNA intercalator. It engages with isolated DNA molecules, inducing unwinding and rewinding processes in superhelical PM2 DNA. Additionally, Luzopeptin A exhibits potent activity against HIV-1 and HIV-2 reverse transcriptases, with IC50 values of 7 nM and 68 nM, respectively. This compound is valuable for research applications in cancer therapy and virology. -
Antibiotic
TAN 420C is an antibiotic exhibiting potent cytotoxic activity specifically targeting lymphocytic leukemia cells. This compound has significant implications for research in cancer treatment and drug development, particularly in exploring therapeutic strategies for hematological malignancies. Its effectiveness in inhibiting the proliferation of leukemia cells makes it a valuable tool for studies focused on leukemia therapies. -
Antibiotic
Parvodicin C2 is a glycopeptide antibiotic that targets bacterial cell wall synthesis. It exhibits significant antibacterial activity against a range of gram-positive bacteria. Due to its mechanism of action, Parvodicin C2 is suitable for research applications focused on antimicrobial susceptibility and the development of new antibiotic therapies. -
Antibiotic
Enduracidin A is a polypeptide antibiotic that primarily targets bacterial cell wall synthesis. Isolated from Streptomyces fungicides, it exhibits significant antimicrobial activity against a range of gram-positive bacteria. This compound is valuable for research applications focused on antibiotic resistance mechanisms and the development of new antibacterial agents. -
Antibiotic
TP-1161 is a novel thiopeptide antibiotic that targets various Gram-positive bacteria, demonstrating strong inhibitory effects with MIC values ranging from 0.25 to 4 μg/mL. This compound is not active against Gram-negative bacteria. TP-1161 serves as a valuable tool for research focused on bacterial infections and the development of new antimicrobial therapies. -
Antitumor Antibiotic
Medermycin is an antitumor antibiotic that primarily exerts its effects through inhibition of various cancer cell lines. It demonstrates potent activity against lymphoma L5178Y progenitor cells and multiple drug-resistant leukemias, with ID50 values of 0.02 μg/mL for L5178Y, 0.006 μg/mL for Adriamycin-resistant cells, and 0.008 μg/mL for Bleomycin-resistant cells, among others. Medermycin is valuable for research applications focused on cancer treatment and the mechanisms of antibiotic resistance. -
Antibacterial Agent
Cefroxadine is an orally active cephalosporin antibiotic that targets bacterial cell wall synthesis. It demonstrates superior antibacterial activity compared to cephalexin against Escherichia coli and Klebsiella pneumoniae, with minimum inhibitory concentration (MIC) values of 3.13 and 1.56 μg/mL, respectively. This compound is suitable for research applications focusing on bacterial infections and antibiotic resistance mechanisms. -
Cephem Antibiotic
Cefcapene is an orally active cephem antibiotic that targets and inactivates chromosome-encoded class C β-lactamases. It exhibits significant antibacterial activity, making it a valuable tool for research focused on antibiotic resistance mechanisms and the efficacy of β-lactam antibiotics. Cefcapene is suitable for studies involving bacterial infections and pharmacological evaluations of antibiotics. -
β-lactam Antibiotic
Piperacillin hydrate is a semisynthetic broad-spectrum β-lactam antibiotic that primarily targets penicillin-binding proteins to exhibit potent bactericidal activity against a range of Gram-negative bacteria and select Gram-positive strains. This compound is frequently utilized in conjunction with β-lactamase inhibitors to enhance its efficacy and overcome resistance mechanisms. Piperacillin hydrate is valuable in various research applications focusing on antimicrobial efficacy and resistance patterns. -
Antibiotic
Kalimantacin A is a potent antibiotic targeting bacterial infections. It demonstrates significant antibacterial activity against a range of Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA). This compound is valuable for research applications focused on antibiotic resistance and the development of new antibacterial agents. -
Antibiotic drug
JH-LPH-33 is a sulfonyl piperazine analog that functions as a potent inhibitor of UDP-2,3-diacylglucosamine pyrophosphate hydrolase (LpxH). It exhibits significant antibiotic activity, demonstrating a minimum inhibitory concentration (MIC) of 0.66 μg/mL. This compound is relevant for research applications focused on bacterial resistance mechanisms and the development of novel antimicrobial therapies. -
Antibacterial peptide
LL-37 GKE is an antibacterial peptide derived from the active domain of LL-37. It exhibits significant antibacterial activity, making it a valuable candidate for research in antibiotic development. LL-37 GKE’s properties offer potential applications in the study of infection control and the enhancement of antimicrobial therapies. -
Antibiotic
Josamycin hydrochloride is an orally active macrolide antibiotic that primarily targets bacterial ribosomes, exhibiting potent antimicrobial activity against a diverse range of pathogens. With a dissociation constant (Kd) of 5.5 nM from the ribosome, it effectively inhibits bacterial protein synthesis. This compound is suitable for research applications related to microbiology and the study of antibiotic resistance mechanisms. -
Antibiotic
Chalcomycin is a macrolide antibiotic that primarily targets gram-positive bacteria, demonstrating potent antimicrobial activity against Staphylococcus aureus and Streptococcus pyogenes. In preclinical studies, Chalcomycin has shown efficacy in protecting mice from infections caused by various staphylococci and streptococci, with a favorable safety profile (LD50 > 2500 mg/kg). This compound is valuable for research in antibiotic resistance and therapeutic applications against bacterial infections. -
Antibiotic
Concanamycin B is a macrolide antibiotic that selectively inhibits vacuolar-type H+-ATPases, with an IC50 value of 5 nM. This inhibition disrupts proton gradient formation, leading to membrane potential alterations in target cells. Concanamycin B is widely used in research to study cellular ion homeostasis, lysosomal function, and autophagy processes. -
Antibiotic
Alalevonadifloxacin mesylate is an orally active antibiotic that targets both Gram-positive and Gram-negative bacteria. Its potent antibacterial activity makes it relevant for research into acute bacterial skin and skin structure infections as well as hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens. This compound demonstrates promise in addressing difficult-to-treat bacterial infections and contributes to the ongoing exploration of new therapeutic options in infectious disease research. -
Antibiotic
Rabelomycin is an antibiotic that primarily targets gram-positive bacteria, demonstrating significant antimicrobial activity. Additionally, it possesses inhibitory effects against inducible nitric oxide synthase (iNOS), with an IC50 value of 63.9 μM. This compound is valuable for research applications focused on bacterial pathogenesis and the modulation of nitric oxide signaling. -
Antibiotic
Cilastatin ammonium salt is an antibiotic that primarily targets Gram-positive cocci, enhancing the efficacy of various beta-lactam antibiotics. With a half-life of 3-4 hours, it is utilized in research to study bacterial resistance mechanisms and evaluate antibiotic combinations. Its role in preserving the pharmacological activity of beta-lactams makes it essential for investigations in microbiology and infectious disease research. -
Antibiotic
Indanomycin is an antibiotic belonging to the pyrroloketoindane class, characterized by its distinct indane ring structure. It exhibits potent bactericidal activity against Gram-positive bacteria, with minimum inhibitory concentration (MIC) values as low as ≤0.2 μg/mL. This compound is essential for research applications targeting bacterial infections and exploring mechanisms of antibiotic resistance. -
Macrolide Antibiotic
Niddamycin is a macrolide antibiotic that targets the 50S ribosomal subunit, effectively inhibiting bacterial protein synthesis. This compound exhibits significant antibacterial activity against a range of Gram-positive bacteria, making it a valuable tool for research into microbial resistance and antimicrobial efficacy. Its mechanism of action makes it suitable for studies focused on ribosome-targeting antibiotics and their potential therapeutic applications. -
Antibiotic
Cetefloxacin is a broad-spectrum antibacterial antibiotic that targets various bacterial pathogens. It demonstrates effective minimum inhibitory concentrations (MIC) ranging from 0.007 to 8 µg/ml. Research indicates that cetefloxacin exhibits protective effects against key pathogens, including Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae, as evidenced in mouse models. This compound is valuable for studies focusing on antibacterial resistance and therapeutic efficacy. -
Antibiotic
Kijanimicin is an antibiotic derived from the microorganism Actinomadura kijaniata SCC 1256. It exhibits potent antibacterial activity against a range of gram-positive bacteria and is primarily utilized in research focused on antimicrobial efficacy and resistance mechanisms. Kijanimicin's unique structure and mode of action make it an important subject of study in the development of new antibiotic therapies. -
Antibiotic
Albicidin is a peptide antibiotic that exhibits potent activity against a range of both Gram-positive and Gram-negative microorganisms. This compound disrupts bacterial cell function, making it a valuable tool for research applications in microbiology and antibiotic susceptibility testing. Its effectiveness against diverse bacterial strains can aid in the exploration of antibiotic resistance mechanisms and the development of new therapeutic strategies.
